Posted by Michael Wonder on 23 Nov 2020
Catalent signs commercial supply agreement with Blueprint Medicines following FDA approval of Gavreto (pralsetinib)
23 November 2020 - Catalent today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of Gavreto (pralsetinib).
Developed by Blueprint Medicines, Gavreto is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer as detected by an FDA approved test.
